Appendix Table 7.
Subgroup analyses for COVID-19-related outcomes by NRTI combination in men with HIV, Veterans Aging Cohort Study, February 2020 – October 2021
| No. events | 18-month risk*, % (95% CI) | Risk difference, % (95% CI) | Risk ratio (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Documented SARS-CoV-2 infection |
Non-Hispanic White | TAF/FTC | 195 | 6.2 | (5.3, 7.1) | 0 (ref.) | 1 (ref.) | ||
| TDF/FTC | 6 | 2.1 | (0.4, 3.9) | −4.1 | (−5.8, −2.0) | 0.34 | (0.07, 0.65) | ||
| ABC/3TC | 42 | 5.3 | (3.6, 7.2) | −1.0 | (−2.8, 1.1) | 0.85 | (0.57, 1.18) | ||
| Other | 32 | 4.8 | (3.1, 6.5) | −1.4 | (−3.2, 0.7) | 0.78 | (0.50, 1.12) | ||
| Non-Hispanic Black | TAF/FTC | 286 | 8.1 | (7.0, 9.0) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 15 | 6.0 | (3.2, 9.0) | −2.1 | (−5.0, 1.2) | 0.74 | (0.39, 1.15) | ||
| ABC/3TC | 127 | 9.1 | (7.7, 10.9) | 1.1 | (−0.6, 3.1) | 1.14 | (0.93, 1.40) | ||
| Other | 73 | 7.0 | (5.4, 8.6) | −1.0 | (−3.0, 0.8) | 0.87 | (0.66, 1.10) | ||
| Age ≥ 50 years | TAF/FTC | 450 | 7.1 | (6.4, 7.7) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 19 | 4.5 | (2.6, 6.6) | −2.6 | (−4.5, −0.4) | 0.64 | (0.38, 0.95) | ||
| ABC/3TC | 150 | 7.2 | (6.1, 8.3) | 0.1 | (−1.1, 1.4) | 1.02 | (0.85, 1.21) | ||
| Other | 107 | 6.0 | (4.9, 7.2) | −1.0 | (−2.3, 0.4) | 0.86 | (0.68, 1.05) | ||
| Age < 50 years | TAF/FTC | 171 | 8.8 | (7.5, 10.2) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 9 | 5.7 | (2.3, 10.0) | −3.0 | (−6.7, 1.1) | 0.65 | (0.26, 1.13) | ||
| ABC/3TC | 51 | 8.2 | (6.0, 10.7) | −0.6 | (−3.1, 2.0) | 0.94 | (0.68, 1.24) | ||
| Other | 27 | 8.5 | (5.5, 11.4) | −0.3 | (−3.8, 2.7) | 0.97 | (0.61, 1.36) | ||
| eGFR ≥ 60 mL/min | TAF/FTC | 393 | 7.2 | (6.4, 7.9) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 18 | 3.6 | (2.1, 5.5) | −3.5 | (−5.2, −1.7) | 0.51 | (0.29, 0.76) | ||
| ABC/3TC | 99 | 7.3 | (5.8, 8.8) | 0.2 | (−1.5, 1.7) | 1.02 | (0.80, 1.24) | ||
| Other | 71 | 6.6 | (5.2, 8.2) | −0.5 | (−2.2, 1.1) | 0.93 | (0.70, 1.16) | ||
| eGFR < 60 mL/min | TAF/FTC | 122 | 8.4 | (6.9, 10.1) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 4 | 8.0 | (0.0, 18.8) | −0.5 | (−7.6, 10.2) | 0.94 | (0.00, 2.32) | ||
| ABC/3TC | 66 | 8.3 | (6.3, 10.4) | −0.2 | (−2.9, 2.3) | 0.98 | (0.70, 1.33) | ||
| Other | 41 | 6.5 | (4.6, 8.6) | −1.9 | (−4.4, 0.7) | 0.77 | (0.52, 1.10) | ||
| COVID-19 hospitalization | Non-Hispanic White | TAF/FTC | 33 | 1.0 | (0.7, 1.5) | 0 (ref.) | 1 (ref.) | ||
| TDF/FTC | 0 | 0.0 | - | −1.0 | - | 0.00 | - | ||
| ABC/3TC | 10 | 1.4 | (0.6, 2.5) | 0.4 | (−0.5, 1.5) | 1.40 | (0.56, 2.79) | ||
| Other | 14 | 2.1 | (1.0, 3.3) | 1.0 | (−0.1, 2.3) | 2.00 | (0.90, 3.77) | ||
| Non-Hispanic Black | TAF/FTC | 88 | 2.6 | (2.0, 3.2) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 3 | 1.1 | (0.0, 2.6) | −1.5 | (−2.7, 0.0) | 0.42 | (0.00, 1.00) | ||
| ABC/3TC | 47 | 3.1 | (2.2, 4.1) | 0.6 | (−0.5, 1.6) | 1.21 | (0.83, 1.73) | ||
| Other | 36 | 3.0 | (2.0, 4.0) | 0.4 | (−0.7, 1.6) | 1.15 | (0.75, 1.69) | ||
| Age ≥ 50 years | TAF/FTC | 136 | 2.2 | (1.8, 2.6) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 4 | 0.9 | (0.2, 2.3) | −1.3 | (−2.1, 0.0) | 0.42 | (0.07, 1.01) | ||
| ABC/3TC | 60 | 2.6 | (2.0, 3.4) | 0.4 | (−0.3, 1.3) | 1.19 | (0.86, 1.64) | ||
| Other | 54 | 2.5 | (1.8, 3.3) | 0.3 | (−0.5, 1.2) | 1.14 | (0.80, 1.61) | ||
| Age < 50 years | TAF/FTC | 20 | 1.1 | (0.6, 1.7) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 1 | 0.7 | (0.0, 2.6) | −0.4 | (−1.5, 1.5) | 0.66 | (0.00, 2.49) | ||
| ABC/3TC | 3 | 0.4 | (0.0, 1.4) | −0.7 | (−1.3, 0.2) | 0.35 | (0.00, 1.25) | ||
| Other | 6 | 2.3 | (0.7, 4.3) | 1.2 | (−0.5, 3.3) | 2.04 | (0.54, 5.33) | ||
| eGFR ≥ 60 mL/min | TAF/FTC | 81 | 1.7 | (1.3, 2.1) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 3 | 0.5 | (0.0, 1.1) | −1.2 | (−1.8, −0.5) | 0.28 | (0.00, 0.67) | ||
| ABC/3TC | 20 | 1.7 | (0.9, 2.5) | 0.0 | (−0.8, 0.9) | 1.00 | (0.55, 1.60) | ||
| Other | 23 | 2.1 | (1.3, 3.1) | 0.5 | (−0.4, 1.5) | 1.27 | (0.76, 2.03) | ||
| eGFR < 60 mL/min | TAF/FTC | 46 | 3.0 | (2.2, 4.1) | 0 (ref.) | 1 (ref.) | |||
| TDF/FTC | 1 | 5.5 | (0.0, 18.6) | 2.5 | (−3.7, 15.6) | 1.82 | (0.00, 6.32) | ||
| ABC/3TC | 29 | 3.4 | (2.1, 4.6) | 0.4 | (−1.2, 1.8) | 1.12 | (0.66, 1.74) | ||
| Other | 27 | 3.7 | (2.4, 5.5) | 0.7 | (−1.0, 2.5) | 1.22 | (0.72, 1.98) | ||
*
Standardized by age, race/ethnicity, smoking status, CD4 cell count, HIV viral load, maximum HIV viral load over the past 12 months, BMI, systolic blood pressure, diastolic blood pressure, average eGFR over the past 12 months, months since February 2020, hospitalization in previous month, comorbidities including: cardsiovascular disease, hypertension, liver disease, chronic pulmonary disease, cancer, chronic kidney disease, alcohol/substance use, diabetes, and dementia.